Search clinical trials for: Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)

Total 33 results

Luye Pharma Group Ltd.
Shandong Luye Pharmaceutical Co., Ltd.

Completed

Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Major Depressive Disorder

China
Sandoz

Completed

To Demonstrate the Relative Bioavailability of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release (ER) Tablets Under Fed Conditions

Allergies
Sandoz

Completed

To Demonstrate the Relative Bioavailability of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release (ER) Tablets Under Fasting Conditions

Allergies
Abbott

Recruiting

Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia

Functional Dyspepsia

Malaysia, Armenia
Cingulate Therapeutics

Completed

CTx-1301 Comparative Bioavailability Study

ADHD

United States
IPCA Laboratories Ltd.

Completed

Bioequivalence Study of Metformin Hydrochloride Extended-Release Tablets USP 750 mg Under Fed Condition

Fasting

India
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Oxybutynin Chloride Extended-Release Tablets 5 mg and Ditropan XL® Tablets 5 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Food Study of Oxybutynin Chloride Extended-Release Tablets 5 mg and Ditropan XL® Tablets 5 mg

Healthy

United States
IPCA Laboratories Ltd.

Completed

Bioequivalence Study of Metformin Hydrochloride Extended-Release Tablets USP 750 mg Under Fasting Condition

Fasting

India
Actavis Inc.

Completed

A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets Under Fasting Conditions

Healthy

United States
Actavis Inc.

Completed

A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets Under Fed Conditions

Healthy

United States
University of Michigan
Food and Drug Administration (FDA)

Recruiting

Pharmacokinetic Study of Single-Dose Modified Release Glipizide in Healthy Volunteers

Human Gastrointestinal Physiology Data

United States
University of Saskatchewan
AstraZeneca

Completed

Melancholic Depression and Insomnia as Predictors of Response to Quetiapine in Patients With Major Depression

Depressive Disorder, Major
Frederiksberg University Hospital

Completed

Opioid Induced Gait Variability

Opioid Induced Motor Disturbances

Denmark
Tris Pharma, Inc.
Premier Research Group plc

Completed

Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD

ADHD

United States
Mylan Pharmaceuticals Inc

Completed

Bioequivalence Study of Divalproex Sodium Delayed-Release Tablets, 500 mg

Healthy

United States
Hospital Universitari de Bellvitge

Terminated

Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression

Depression

Spain
Actavis Inc.

Completed

A Relative Bioavailability Study of Bupropion Sustained Release 150 mg Tablets Under Fasting Conditions

Healthy

United States
RedHill Biopharma Limited

Completed

Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

Irritable Bowel Syndrome With Diarrhea

United States
Johns Hopkins University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Rapid HIV Treatment Initiation, Access and Engagement in Care

Human Immunodeficiency Virus

United States
Ranbaxy Laboratories Limited

Completed

Bioequivalence Study on Pseudoephedrine HCl 120 mg ER Tablets Under Fasting Conditions

Healthy

Canada
Benha University

Recruiting

Mirabegron 25 mg for Treatment of Primary Nocturnal Enuresis

Nocturnal Enuresis

Egypt
Fundación Leucemia y Linfoma, Spain
Roche Pharma AG

Completed

Rituximab and CVP Plus Interferon for Follicular Non Hodgkins Lymphoma (NHL) (LNH-Pro-05)

Non-Hodgkin's Lymphoma

Spain
Danish Headache Center

Completed

Multiomics After Headache Provocation of People Who Are Unable to Have Headache

Healthy | Headache

Denmark
Dr. Reddy's Laboratories Limited

Completed

Bioequivalence Study of Guaifenesin and Pseudoephedrine Hydrochloride Extended Release Tablets 1200/120 mg Under Fasting Conditions

Healthy

India
University of Basrah

Recruiting

Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic Control

Type2diabetes

Iraq
Galenicum Health

Completed

Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions.

Diabetes Mellitus, Type 2 | Bioequivalence

Mexico
Galenicum Health

Completed

Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.

Diabetes Mellitus, Type 2 | Bioequivalence

Mexico
Adams Respiratory Therapeutics

Completed

Phase 4 Study - Mucinex D as Adjunct Therapy

Bronchitis | Acute Respiratory Infection | Rhinosinusitis

United States
Radboud University Medical Center

Active, not recruiting

Efficacy of Diltiazem to Improve Coronary Microvascular Dysfunction: a Randomized Clinical Trial (EDIT-CMD)

Coronary Vasospasm | Microvascular Angina | Microvascular Ischemia of Myocardium

Netherlands
Cardresearch

Recruiting

A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial (REVIVE)

Chronic Fatigue Syndrome | Long COVID-19 Syndrome

Brazil
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

Metastatic Malignant Neoplasm in the Liver | Advanced Malignant Neoplasm | Refractory Malignant Neoplasm | Colorectal Carcinoma Metastatic in the Liver

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Parsaclisib With or Without Polatuzumab Vedotin Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma | Indolent Non-Hodgkin Lymphoma | Ann Arbor Stage II Diffuse Large B-Cell Lymphoma | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | High Grade... and other conditions

United States

3

Subscribe